Efficacy and safety of decitabine combined with low-dose cytarabine,aclarubicin,and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation

著录项

• 来源
  《中华医学杂志（英文版）》 |2021年第12期|1477-1479|共3页
• 作者

  Si-Si Chen; Qian Sun; Lan Cao; Wen-Zhong Wu; Yue Xie; Chun Qiao; Jian-Yong Li; Si-Xuan Qian; Ming Hong;

  展开▼
• 作者单位

  Department of Hematology The Affiliated Yixing Hospital of Jiangsu University Wuxi Jiangsu 214200 China;

  Department of Hematology The First Affiliated Hospital of Nanjing Medical University Jiangsu Province Hospital Nanjing Jiangsu 210029 China;

  Key Laboratory of Hematology of Nanjing Medical University Nanjing Jiangsu 210029 China;

  Collaborative Innovation Center for Cancer Personalized Medicine Nanjing Jiangsu 210029 China;

  pukou CLL Center Pukou division of Jiangsu Province Hospital Nanjing Jiangsu 211899 China;

  Department of Hematology The First Affiliated Hospital of Nanjing Medical University Jiangsu Province Hospital Nanjing Jiangsu 210029 China;

  Key Laboratory of Hematology of Nanjing Medical University Nanjing Jiangsu 210029 China;

  Collaborative Innovation Center for Cancer Personalized Medicine Nanjing Jiangsu 210029 China;

  Pukou CLL Center Pukou division of Jiangsu Province Hospital Nanjing Jiangsu 211899 China;

  Department of Hematology The Affiliated Yixing Hospital of Jiangsu University Wuxi Jiangsu 214200 China;

  Department of Hematology The Affiliated Yixing Hospital of Jiangsu University Wuxi Jiangsu 214200 China;

  Department of Hematology The First Affiliated Hospital of Nanjing Medical University Jiangsu Province Hospital Nanjing Jiangsu 210029 China;

  Key Laboratory of Hematology of Nanjing Medical University Nanjing Jiangsu 210029 China;

  Collaborative Innovation Center for Cancer Personalized Medicine Nanjing Jiangsu 210029 China;

  Pukou CLL Center Pukou division of Jiangsu Province Hospital Nanjing Jiangsu 211899 China;

  Department of Hematology The First Affiliated Hospital of Nanjing Medical University Jiangsu Province Hospital Nanjing Jiangsu 210029 China;

  Key Laboratory of Hematology of Nanjing Medical University Nanjing Jiangsu 210029 China;

  Collaborative Innovation Center for Cancer Personalized Medicine Nanjing Jiangsu 210029 China;

  Pukou CLL Center Pukou division of Jiangsu Province Hospital Nanjing Jiangsu 211899 China;

  Department of Hematology The First Affiliated Hospital of Nanjing Medical University Jiangsu Province Hospital Nanjing Jiangsu 210029 China;

  Key Laboratory of Hematology of Nanjing Medical University Nanjing Jiangsu 210029 China;

  Collaborative Innovation Center for Cancer Personalized Medicine Nanjing Jiangsu 210029 China;

  Pukou CLL Center Pukou division of Jiangsu Province Hospital Nanjing Jiangsu 211899 China;

  Department of Hematology The First Affiliated Hospital of Nanjing Medical University Jiangsu Province Hospital Nanjing Jiangsu 210029 China;

  Key Laboratory of Hematology of Nanjing Medical University Nanjing Jiangsu 210029 China;

  Collaborative Innovation Center for Cancer Personalized Medicine Nanjing Jiangsu 210029 China;

  Pukou CLL Center Pukou division of Jiangsu Province Hospital Nanjing Jiangsu 211899 China;

  展开▼
• 原文格式 PDF
• 正文语种 eng
• 中图分类
• 关键词